Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹9 Cr
Revenue (TTM)
₹15 Cr
Net Profit (TTM)
₹1 Cr
ROE
13.9 %
ROCE
18.1 %
P/E Ratio
8.6
P/B Ratio
2
Industry P/E
49.99
EV/EBITDA
5.7
Div. Yield
0 %
Debt to Equity
0
Book Value
₹10.2
EPS
₹2.3
Face value
10
Shares outstanding
4,480,500
CFO
₹1.50 Cr
EBITDA
₹3.83 Cr
Net Profit
₹2.75 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Unjha Formulations
| -20.0 | -7.8 | -21.1 | -12.7 | 17.0 | 19.7 | 7.8 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Unjha Formulations
| -18.4 | 77.6 | 6.2 | 42.0 | 22.5 | 15.3 | -6.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Unjha Formulations
|
20.0 | 9.0 | 14.9 | 1.0 | 7.8 | 27.8 | 8.6 | 2.0 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,547.6 | 29,354.2 | 8,850.1 | 894.8 | 15.2 | 19.8 | 33.7 | 5.9 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Unjha Formulations Limited manufactures and sells ayurvedic products in India. The company offers sat-isabgol and isabgo husk formulation in elaichi flavor under the Anchor name; and isabgol powder in orange flavor under the Fibron and Fibron SF... names, as well as natural fiber drink products. It also exports its products. The company was incorporated in 1994 and is based in Sidhpur, India. Read more
Incorporated
1994
Chairman
Jashodaben S Patel
Managing Director
Krutiben M Patel
Headquarters
Sidhpur, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Unjha Formulations Ltd is ₹20.00 (BSE) as of 02-Apr-2026 IST. Unjha Formulations Ltd has given a return of 16.96% in the last 3 years.
The P/E ratio of Unjha Formulations Ltd is 8.62 times as on 02-Apr-2026, a 83 discount to its peers’ median range of 49.99 times.
The P/B ratio of Unjha Formulations Ltd is 1.95 times as on 02-Apr-2026, a 74 discount to its peers’ median range of 7.36 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
23.99
|
3.11
|
|
2024
|
30.47
|
3.10
|
|
2023
|
19.83
|
2.28
|
|
2022
|
16.66
|
1.94
|
|
2021
|
36.78
|
1.99
|
The 52-week high and low of Unjha Formulations Ltd are Rs 30.40 and Rs 18.99 as of 05-Apr-2026.
Unjha Formulations Ltd has a market capitalisation of ₹ 9 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Unjha Formulations Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.50
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.